Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06534190 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD8 PET Imaging in Metastatic Solid Tumours

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 4 sitesv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2024 to Mar 11, 2025 · Site details revised at 4 of 4 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2024 to Mar 11, 2025
    • Site details revised at 4 of 4 sites
  3. Start date: Aug 2024 to Dec 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.
Trial Details
NCT Number NCT06534190
Lead Sponsor University Medical Center Groningen
Conditions Locally Advanced Solid Tumor
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov